Compare Indoco Remedies with Bajaj Finance - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs BAJAJ FINANCE - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

BAJAJ FINANCE 
   Change

Established in 1987, Bajaj Finance Ltd is a subsidiary of Bajaj Finserv Ltd, the financial services arm of the Bajaj Group. In the early days, Bajaj Finance provided loans for two and three-wheelers manufactured by Bajaj Auto Ltd. Over the years, the... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES BAJAJ FINANCE INDOCO REMEDIES/
BAJAJ FINANCE
 
P/E (TTM) x 54.9 43.1 127.4% View Chart
P/BV x 2.2 12.9 16.8% View Chart
Dividend Yield % 0.6 0.1 625.9%  

Financials

 INDOCO REMEDIES   BAJAJ FINANCE
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
BAJAJ FINANCE
Mar-18
INDOCO REMEDIES/
BAJAJ FINANCE
5-Yr Chart
Click to enlarge
High Rs3171,989 16.0%   
Low Rs1781,153 15.5%   
Sales per share (Unadj.) Rs113.11,168.6 9.7%  
Earnings per share (Unadj.) Rs4.5232.5 1.9%  
Cash flow per share (Unadj.) Rs11.8241.3 4.9%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.40.3 158.5%  
Book value per share (Unadj.) Rs73.21,438.4 5.1%  
Shares outstanding (eoy) m92.15115.03 80.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.3 163.0%   
Avg P/E ratio x55.56.8 820.9%  
P/CF ratio (eoy) x21.06.5 322.2%  
Price / Book Value ratio x3.41.1 309.7%  
Dividend payout %22.41.7 1,301.2%   
Avg Mkt Cap Rs m22,830180,689 12.6%   
No. of employees `0005.515.3 35.7%   
Total wages/salary Rs m2,20914,196 15.6%   
Avg. sales/employee Rs Th1,910.18,805.2 21.7%   
Avg. wages/employee Rs Th405.0929.9 43.5%   
Avg. net profit/employee Rs Th75.51,751.7 4.3%   
INCOME DATA
Net Sales Rs m10,419134,420 7.8%  
Other income Rs m47239 19.6%   
Total revenues Rs m10,466134,659 7.8%   
Gross profit Rs m1,34988,087 1.5%  
Depreciation Rs m6771,021 66.3%   
Interest Rs m23546,343 0.5%   
Profit before tax Rs m48440,962 1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7214,221 0.5%   
Profit after tax Rs m41226,741 1.5%  
Gross profit margin %12.965.5 19.8%  
Effective tax rate %15.034.7 43.1%   
Net profit margin %4.019.9 19.9%  
BALANCE SHEET DATA
Current assets Rs m5,373377,806 1.4%   
Current liabilities Rs m4,157227,458 1.8%   
Net working cap to sales %11.7111.8 10.4%  
Current ratio x1.31.7 77.8%  
Inventory Days Days680-  
Debtors Days Days73932 7.8%  
Net fixed assets Rs m6,2444,670 133.7%   
Share capital Rs m1841,150 16.0%   
"Free" reserves Rs m6,566164,306 4.0%   
Net worth Rs m6,750165,457 4.1%   
Long term debt Rs m1,233458,963 0.3%   
Total assets Rs m12,363868,243 1.4%  
Interest coverage x3.11.9 162.4%   
Debt to equity ratio x0.22.8 6.6%  
Sales to assets ratio x0.80.2 544.4%   
Return on assets %5.28.4 62.1%  
Return on equity %6.116.2 37.7%  
Return on capital %9.014.0 64.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,143315 362.5%   
Net fx Rs m2,619-315 -830.3%   
CASH FLOW
From Operations Rs m1,227-204,614 -0.6%  
From Investments Rs m-1,3609,712 -14.0%  
From Financial Activity Rs m-388195,033 -0.2%  
Net Cashflow Rs m-521131 -397.7%  

Share Holding

Indian Promoters % 59.2 61.6 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 7.1 176.1%  
FIIs % 6.0 12.2 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 19.1 117.3%  
Shareholders   12,805 19,952 64.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   COMMEX TECHNOLOGY  KOTHARI PRODUCTS  MOTILAL OSWAL  JSW HOLDINGS  GREENPLY INDUSTRIES  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

BAJAJ FINANCE Announces Quarterly Results (2QFY20); Net Profit Up 63.1% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, BAJAJ FINANCE has posted a net profit of Rs 15 bn (up 63.1% YoY). Sales on the other hand came in at Rs 63 bn (up 48.5% YoY). Read on for a complete analysis of BAJAJ FINANCE's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

BAJAJ FINANCE Announces Quarterly Results (1QFY20); Net Profit Up 43.0% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, BAJAJ FINANCE has posted a net profit of Rs 12 bn (up 43.0% YoY). Sales on the other hand came in at Rs 58 bn (up 47.4% YoY). Read on for a complete analysis of BAJAJ FINANCE's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Dec 6, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS